Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

A Phase II, Randomized, Multi-Centre, Open-Label, Active-Controlled, Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

This is a randomized open label dose finding study to evaluate the efficacy and safety of F-627 on women with Stage I-IV breast cancer receiving chemotherapy treatment.

Study Overview

• Status: Completed
• Conditions: Breast Cancer; Neutropenia
• Intervention / Treatment: Drug: F-627; Drug: Neulasta® (pegfilgrastim)

Detailed Description

This is a randomized, multi-center, dose finding, open label, positive controlled Phase II study of the efficacy and safety of once-per-cycle of F-627 compared with Neulasta® (pegfilgrastim) in women with breast cancer who are receiving myelotoxic chemotherapy (TC: docetaxel + cyclophosphamide or TAC: docetaxel + doxorubicin + cyclophosphamide).

The primary objective of this study is to evaluate the efficacy and safety of various single cycle doses of F-627 as compared with the standard dosing of Neulasta® (pegfilgrastim) in breast cancer patients experiencing myelotoxic chemotherapy. Myelotoxicity in this study will be defined by the duration of moderate neutropenia; the number of days in which the patient has had an absolute neutrophil count (ANC) < 1.0 × 10^9/L during the first cycle of their chemotherapy treatment (each chemotherapy cycle is expected to last 21 days). This, by definition, includes grade 3 (moderate) and grade 4 (severe) neutropenia. Doses of F-627 to be tested for subjects receiving TC chemotherapy are 80 µg/kg/dose, 240 µg/kg/dose, and 320 µg/kg/dose. For subjects receiving TAC chemotherapy, only 240 µg/kg/dose and 320 µg/kg/dose are to be tested.

• Study Type: Interventional
• Enrollment (Actual): 232
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Indiana
    • Anderson, Indiana, United States, 46011
      • Community Hospital of Anderson

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Show evidence of a signed (personally or by a legally acceptable representative) and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the trial.
• Females ≥ 18 years of age.
• Diagnosed with Stage I-IV breast cancer.
• Subject is scheduled to undergo 4 cycles of TC or TAC chemotherapy (Taxotere®, doxorubicin and cyclophosphamide, 75, 50 and 600 mg/m2, respectively).
• ECOG Performance status of ≤ 2.
• White Blood Cell count (WBC) ≥ 4.0 × 109/L, hemoglobin ≥ 11.5 g/dL and a platelet count ≥ 150 × 109/L.
• Demonstrate adequate renal, hepatic function (Liver function tests (ALT, AST, alkaline phosphatase and total bilirubin)) should be less than 2.5x upper limits of normal (ULN). Serum creatinine should be less than 1.7x ULN.
• All subjects must agree to use at least one of the following types of contraception: intrauterine device, implantable progesterone device, progesterone intramuscular injection, or oral contraceptive, which has been started at least one month prior to visit one and will continue for the duration of the trial. The contraceptive patch or condom use with spermicide are also acceptable forms of contraception as long as they will be used continually throughout the duration of the trial.

Exclusion Criteria:

• Subject is <18 or ≥ 75 years of age.
• Disease progression has occurred while receiving a taxane regimen.
• Subject has undergone radiation therapy within 4 weeks of enrollment.
• Subject has undergone bone marrow or stem-cell transplantation.
• Subject has a history of prior malignancy other than breast cancer.
• Subjects that have used G-CSF within 6 weeks of the screening period are also excluded
• Subject has had chemotherapy within 365 days of screening
• Subject has documented congestive heart failure, cardiomyopathy or myocardial infarction by clinical diagnosis, ECG test, or any other relevant test.
• History of alcohol or drug abuse that would interfere with the ability to be compliant with the study procedure.
• Unwillingness to participate in the study.
• Any underlying medical condition that, in the Investigator's opinion, would make the administration of study drug hazardous to the patient or that would obscure the interpretation of adverse events.
• Receiving other investigational drugs or biologics within 1 month or five half lives of enrollment.
• Any condition, which can cause splenomegaly.
• Chronic constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease.
• ALT, AST, alkaline phosphatase > 2.5 upper limit of normal.
• Patients with active infection, or known to be infected with chronic active Hepatitis B within the last 1 year (unless shown at the time of study entry to be Hepatitis B antigen negative), or having any history of Hepatitis C.
• Women who are pregnant or breast-feeding.
• Patients known to be seropositive for HIV, or who have had an AIDS defining illness or a known immunodeficiency disorder.
• Patients with a history of tuberculosis or exposure to tuberculosis. Patients that have received a prior chest X-ray for suspicion of tuberculosis are also excluded unless they have been confirmed to be PPD negative or they had latent tuberculosis that has been previously treated.
• Subjects with Sickle Cell disease
• Subjects with known hypersensitivity to E.coli derived proteins' pegfilgrastim' filgrastim, or any other component of the study drug.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 80 µg/kg/dose of F-627; This dose of F-627 given only to subjects that are to have TC chemotherapy.	Drug: F-627; subcutaneous injection given 1 per chemotherapy.
Experimental: 240 µg/kg/dose of F-627; This dose of F-627 given to subjects receiving TC or TAC chemotherapy.	Drug: F-627; subcutaneous injection given 1 per chemotherapy.
Experimental: 320 µg/kg/dose of F-627; This dose of F-627 given to subjects receiving TC or TAC chemotherapy.	Drug: F-627; subcutaneous injection given 1 per chemotherapy.
Active Comparator: Neulasta® (pegfilgrastim); Given to subjects receiving TC or TAC chemotherapy.	Drug: Neulasta® (pegfilgrastim); Single dose injection given once per chemotherapy cycle.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Duration of Moderate Neurtopenia Post First Chemotherapy Administration	Number of days In which the patient has had an absolute neutrophil count (ANC) Level < 2.0 x 10^9/L after first cycle of chemotherapy	The first of 4, 21 Day Chemotherapy Cycles

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Duration in Days of Grade 3 and Grade 4 Neutropenia for All 4 Chemotherapy Cycles.	Number of days In which the patient has had an ANC < 1.0 × 10^9/L (Grade 3) or ANC < .5 × 10^9/L (Grade 4) post each chemotherapy	Measured for each of the 4, 21 day chemotherapy cycles.
The Incidence Rate of Febrile Neutropenia	The incidence rate of febrile neutropenia for each arm of the study will be recorded for 4 chemotherapy cycles. Each cycle is expected to last 21 Days.	Measured for each of the 4, 21 day chemotherapy cycles.
The Duration in Days of Total Grade 2-4 Neutropenia	Number of says in which the patient has had an ANC Level ANC < 1.5 × 109/L) post each chemotherapy	Measured for each of the 4, 21 day chemotherapy cycles.
The Time to ANC Recovery Post Nadir	The time to ANC recovery post nadir for each patient, for each of their chemotherapy cycles will be recorded; recovery for this protocol is defined as achieving an ANC ≥ 2.0 × 10^9/L after the expected ANC nadir (expected nadir is typically 4-6 days post chemotherapy administration). Each chemotherapy cycle is expected to last 21 days.	Measured for each of the 4, 21 day chemotherapy cycles.
The Incidence Rates of Grade 2, Grade 3, and Grade 4 Neutropenia for All Chemotherapy Cycles	The incidence rate of mild, moderate and sever neutropenia for each arm of the study will be recorded for 4 chemotherapy cycles. Each cycle is expected to last 21 Days.	Measured for each of the 4, 21 day chemotherapy cycles.
The Depth of the ANC Nadir for All Chemotherapy Cycles	The depth of ANC nadir for each cycle is defined as the minimal ANC value for a subject in each chemotherapy cycle. The depth of the ANC nadir for each arm of the study will be recorded for 4 chemotherapy cycles.	Measured for each of the 4, 21 day chemotherapy cycles

Collaborators and Investigators

• Sponsor: EVIVE Biotechnology

Study record dates

Study Major Dates

• Study Start: June 1, 2012
• Primary Completion (Actual): December 1, 2014
• Study Completion (Actual): December 1, 2014

Study Registration Dates

• First Submitted: April 27, 2012
• First Submitted That Met QC Criteria: July 19, 2012
• First Posted (Estimate): July 24, 2012

Study Record Updates

• Last Update Posted (Actual): October 3, 2018
• Last Update Submitted That Met QC Criteria: October 2, 2018
• Last Verified: October 1, 2018

More Information

Terms related to this study

• Keywords: Breast Cancer; efficacy and safety; Neulasta; pegfilgrastim; Taxotere Chemotherapy; single cycle doses of F-627
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Hematologic Diseases; Breast Diseases; Agranulocytosis; Leukopenia; Leukocyte Disorders; Breast Neoplasms; Neutropenia
• Other Study ID Numbers: GC-627-02

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No